THE WORLD OF PHARMACEUTICAL AND BIOTECH PATENT LITIGATION IS MOVING INTO UNCHARTERED TERRITORY AND THERE IS MUCH TO CLARIFY.
The imminent commencement of the Unified Patent Court continues to dominate the thoughts and concerns of every IP and Pharma expert. It goes without saying, devising an effective patent litigation strategy in an unknown and untested regime does not come without risk. There also remain many unanswered questions surrounding the transition period, the dilemma and transparency of opting out and the implementation of SPC’s within the new regime amongst others, and such uncertainty creates a challenging patent litigation environment.
Case law developments over the past year on Biosimilars, Supplementary Protection Certificates and Second Medical Use Patents have been significant and have impacted heavily on the patent litigation landscape. Most notably, the repercussions of the landmark Lyrica decision on industry players and stakeholders alike continue to be felt.
C5’s 8th Pharma & Biotech Patent Litigation conference will provide an invaluable focus for analysis of all the fundamental changes affecting pharma and biotech patents across Europe and the US and consider the impact of judicial decisions in the national courts on your litigation strategies.
Receive an in-depth understanding of the hottest topics, equipping you to alter and strengthen your litigation strategies and tailor your techniques to the latest challenges in today’s constantly changing patent landscape.